The QualityStocks Daily Thursday, April 11th, 2019

Today's Top 3 Investment Newsletters

OTCtipReporter (FTFT) +162.17%

StockMarketWatch (PHUN) +70.11%

TopPennyStockMovers (ZOOM) +54.55%

The QualityStocks Daily Stock List

Cyber Security 1 AB (CYBNY)

Stockhouse, Morningstar, Teletrader, Dividend Investor, 4-Traders, YCharts, GuruFocus, GlobeNewswire, Seeking Alpha, and Trading View reported previously on Cyber Security 1 AB (CYBNY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cyber Security 1 AB (CYBNY) is a global leader in Cyber Security. It provides cyber resilience solutions and conducts its operations via physical presences in Sweden, South Africa, the UK, Kenya, Germany, Austria, Turkey, Greece, Italy, the Ukraine and the United Arab Emirates (UAE). The Company previously went by the name Cognosec AB (publ). It changed its corporate name to Cyber Security 1 AB in July of last year. Cyber Security 1 AB has its corporate headquarters in Stockholm, Sweden.

Providing governance, risk, and compliance cybersecurity solutions, the Company offers solutions for client and information systems audit, penetration testing, application security assessment, and security monitoring. It also offers solutions for urgent incident response and crisis management, data leakage and loss prevention, and network security and management.

Cyber Security 1 is coming off its best year ever with record quarterly and annual revenues. The Company also has an increasing global footprint, an impressive client list, a flourishing mergers and acquisition (M&A) strategy and this year a newly appointed Chief Executive Officer (CEO). Moreover, Cyber Security 1 had revenues of 44.54m EUR in 2018 and employed 239 personnel at the end of Q4 2018.

Cyber Security 1 will enter its new phase with Mr. Nick Viney, its newly appointed CEO. Mr. Viney joined the Company after a successful 7-year career at McAfee. His resume also consists of a number of senior management positions at several of the world's largest international technology companies, including Microsoft, Google, eBay and Arthur Andersen.

This past February, Cyber Security 1 AB announced an exclusive five-year partnership with Formula 1®, which is the world's premier motorsport series. The Company will provide Formula 1® with a variety of resilient solutions, designed to enhance and secure Formula 1's infrastructure from potential cyber threats. Cyber Security 1 will work closely with the Information Technology (IT) department at Formula 1®, delivering several key projects. This includes consultancy, implementation, as well as advisory.

Last month, Cyber Security 1 AB announced the signing of exclusive Heads of Terms of Agreement pursuant to the acquisition of IntaForensics. Since IntaForensics' creation in 2006, the business has grown globally to provide the broadest array of Digital Forensic and Cyber Security Services from its England headquarters.

IntaForensics is one of the fastest growing Digital Forensic Services providers worldwide. It is one of a few organizations that possesses the prestigious ISO/IEC 17025 Laboratory Standard. It is also accredited to ISO/IEC 27001 and ISO 9001. The business is accredited by the PCI Security Standards Council as a Qualified Security Assessor and a PCI Forensics Investigator (QSA, PFI).

Cyber Security 1 AB (CYBNY), closed Thursday's trading session at $1.67, up 15.17%, on 600 volume with 2 trades. The average volume for the last 3 months is 296 and the stock's 52-week low/high is $1.259/$5.00.

chart

TerrAscend Corp. (TRSSF)

Street Signals, Hottest Stock Picks, Profit Confidential, GuruFocus, Small Cap Power, Energy and Capital, MicroCapDaily, Trading View, Financial Content, CannabisMarketCap, Market Screener, The Seed Investor, Wallet Investor, Midas Letter, New Cannabis Ventures, Barchart, Seeking Alpha, The Street, MarketWatch, and Stockhouse reported earlier on TerrAscend Corp. (TRSSF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

TerrAscend Corp. is a biopharmaceutical and wellness company listed on the OTC Markets Group's OTCQX. The Company's commitment is to quality products, brands, and services for the worldwide cannabinoid market. TerrAscend participates in the medical and legal adult-use market in Canada and in U.S. states where cannabis has been legalized for therapeutic or adult-use. The Company has its corporate office in Mississauga, Ontario.

TerrAscend operates several synergistic businesses. These include Arise Bioscience, Inc., a manufacturer and distributor of hemp-derived products, Ascendant Laboratories, Inc., a biotechnology and licensing Company dedicated to the continuous improvement of cannabinoid expressing plants, and Solace RX, Inc., a proposed drug preparation premises centered on the development of novel formulations and dosage forms. TerrAscend's brands include Haven St. Premium Cannabis; and Knüba Naturals, which is a line of premium cannabis products.

The Company has its facility built to GMP requirements. The facility is 67,300 sq. ft., located in Mississauga. It features premium hydroponic cultivation and products are lab tested to the highest standards. The facility has sterile & non-sterile drug compounding capabilities.

This past January, TerrAscend announced the closing of the earlier reported asset acquisition of Grander Distribution, LLC. Grander is an industry leader in the production and distribution of unique hemp-derived wellness products. Grander's whole-plant hemp extract products are made in the United States and are available for sale in approximately 10,000 retail locations around the world.

Recently, TerrAscend announced the signing of definitive securities purchase agreements facilitating a major investment in three entities in California operating the award-winning retail dispensary brand known as "The Apothecarium". In addition, the purchase agreements include the acquisitions of a vertically integrated operation in Nevada with cultivation, edible manufacturing and an Apothecarium retail location, and also Valhalla Confections, a provider of top premium edible products.

Last month, TerrAscend announced preliminary Q4 and full year revenue ending December 31, 2018 of CAD$4.8 million and CAD$6.6 million, respectively. Audited year end results will be published on the morning of April 25, 2019 followed by an Investor Day where TerrAscend will provide full year 2019 financial guidance.

TerrAscend Corp. (TRSSF), closed Thursday's trading session at $5.3347, down 0.88%, on 99,681 volume with 274 trades. The average volume for the last 3 months is 60,880 and the stock's 52-week low/high is $2.5594/$10.44.

chart

AMMO, Inc. (POWW)

Infront Analytics, Simply Wall St, GlobeNewswire, GuruFocus, Morningstar, Wallet Investor, YCharts, Barchart, The Street, Stockopedia, Stockwatch, Dividend Investor, Stockhouse, 4-Traders, InvestorsHub, Stockawiki, Investors Hangout, Business Insider, Market Screener, Trading View, MarketWatch, and Seeking Alpha reported previously on AMMO, Inc. (POWW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AMMO, Inc. is a technology leader and premier American ammunitions manufacturer listed on the OTC Markets' OTCQB. The Company designs and manufactures products for an array of aptitudes. This includes law enforcement, military, hunting, sport shooting and self-defence. Established in 2016, AMMO has its corporate office in Scottsdale, Arizona. AMMO operates a munitions manufacturing facility in Payson, Arizona, and a brass casings manufacturing facility in Manitowoc, Wisconsin.

The Company promotes branded munitions. These include its patented STREAK™ Visual Ammunition, the Jesse James line of munitions and accessories, /stelTH/ subsonic munitions, O.W.L. Technologies®, TAC-PTM Tactical Precision Defense munitions, and OPS (One Precise Shot). OPS is a lead-free frangible tactical line of munitions for self-defence.

The ammunition the Company builds performs like high end custom hand loaded ammunition. AMMO works to be the foremost innovator of center-fire ammunition for military, law enforcement, and civilians. Every load is developed for a specific purpose.

The emphasis is on consistency, accuracy, and, in some cases, felt recoil. Each round is designed, manufactured, inspected and packaged to bring a premier shooting experience to AMMO's end consumer. Moreover, the Company's HyperClean technology enables its customers to shoot more and clean less.

Recently, AMMO announced that the rollout of its STREAK™ Visual Ammunition product line to 142 Bass Pro Shops and Cabela's locations is complete. AMMO also announced that its STREAK products will be featured in an upcoming Bass Pro Shops national ad campaign and within their renowned retail catalogs.

In March, AMMO announced it closed the strategic acquisition of Jagemann Sporting Group's Wisconsin Casings division (Jagemann Casings). Jagemann's Casing Division is located in Manitowoc Wisconsin, the headquarters for Jagemann Stamping, the 73-year-old parent company established to serve the automotive industry with specialty precision metal stamped parts. The Jagemann Casings operations will continue to be led by its present general manager and an established manufacturing team that will manage the business and operations under the direction of AMMO, Inc.

The manufacturing operations will remain in Manitowoc, Wisconsin. Jagemann Chief Executive Officer, Mr. Tom Jagemann, will continue to lead Jagemann Stamping Company and concentrate on its core business as a foremost manufacturer of deep drawn, progressive and fine blanking metal stampings. Mr. Jagemann has been appointed as a Director on AMMO, Inc.'s Board in conjunction with the closing of the transaction.

In March, AMMO was awarded its first U.S. Law Enforcement contract within its home state of Arizona. Under the contract, IT will be supplying its "AMMO Branded" ammunition to include pistol and certain calibers of rifle rounds.

AMMO, Inc. (POWW), closed Thursday's trading session at $3.00, up 4.90%, on 4,310 volume with 5 trades. The average volume for the last 3 months is 10,827 and the stock's 52-week low/high is $1.50/$6.50.

chart

Body and Mind, Inc. (BMMJ)

MicroSmallCap, Penny Stock Tweets, Dividend Investor, Wallmine, Market News Updates, PotStockNews, Investor Ideas, Stockhouse, New Cannabis Ventures, Wallet Investor, Trading View, Simply Wall St, The Street, Barchart, InvestorsHub, Insider Financial, Morningstar, Midas Letter, Canadian Insider, and GuruFocus reported on Body and Mind, Inc. (BMMJ), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Body and Mind, Inc. invests in high quality medical and recreational cannabis cultivation, production and retail. The Company's wholly-owned Nevada subsidiary was awarded one of the first medical marijuana cultivation licences. In addition, it holds cultivation and production licenses. Body and Mind (BaM) products include dried flower, edibles, topicals, extracts, and GPEN Gio cartridges. The Company lists on the OTC Markets and is based in Vancouver, British Columbia.

Body and Mind's cannabis plants are grown with hands-on care in small batches. Moreover, the Company never uses synthetic pesticides. It offers an assortment of strains, available in flower, vapes, pre-rolls and concentrates.

Body and Mind has collected, for several years', elite cannabis plants from all over the world.  Through carefully crossbreeding these plants, the Company has developed strains that give what it states are the perfect balance of body and mind benefits.

This past February, Body and Mind announced that the Clubhouse dispensary in Ohio received final approvals from the Ohio Board of Pharmacy and Elyria City Council to open the dispensary on February 22, 2019. Nevada Medical Group LLC (NMG Nevada), a wholly-owned subsidiary of the Company, recently entered into a definitive agreement where NMG Nevada will acquire 100 percent ownership of NMG Ohio LLC.

NMG Nevada, which previously held a 30 percent interest in NMG Ohio, will purchase the remaining 70 percent interest for fair value consideration of USD $3,150,000. NMG Ohio owns a dispensary in Loraine County, Elyria and a production license.

In addition, last month, Body and Mind announced expansion into Arkansas with in-State partner, Comprehensive Care Group LLC (CCG). The companies will work together to develop a medical marijuana dispensary facility in West Memphis, Arkansas. Medical marijuana dispensaries in Arkansas are licensed for retail sales and cultivation of up to 50 plants within the same facility.

Mr. Robert Hasman, director of the Company, said, "We are pleased to have been successful in assisting Comprehensive Care Group obtain a dispensary license through the application process, an initiative that creates significant value for all stakeholders. Secondly, this deal provides BaM shareholders greater retail exposure, a fourth platform for growth and a path to launch some of its' own products to the medical patients of Arkansas. We are proud to have been selected as one of only 32 dispensary licenses awarded in Arkansas and look forward to working with Comprehensive Care Group."

Body and Mind, Inc. (BMMJ), closed Thursday's trading session at $1.46, up 20.04%, on 791,838 volume with 613 trades. The average volume for the last 3 months is 160,351 and the stock's 52-week low/high is $0.25/$1.48.

chart

Captor Capital Corp. (CPTRF)

Stock Talk Today, InvestorsHub, GlobeNewswire, Capital Market Review, Midas Letter, MarketWatch, TMXmoney, Stockhouse, Otc.watch, Seeking Alpha, GuruFocus, Stockwatch, The Street, Market Screener, YCharts, Dividend Investor, Baystreet, Morningstar, Zacks, Investors Hangout, Barchart, and Investorx reported earlier on Captor Capital Corp. (CPTRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Captor Capital Corp. is a vertically integrated investment company headquartered in Toronto, Ontario. It cultivates, manufactures and distributes recreational and medical marijuana based products to consumers via its leading brands and dispensary retail stores. At present, the Company has several revenue generating cannabis investments. This includes the CHAI Cannabis Co. dispensaries in Santa Cruz and Monterey. In addition, it owns Mellow Extracts, a highly regarded producer of cannabis extracts based in Costa Mesa, California.

Captor Capital owns and operates advanced growing facilities that produce consistent high-quality, contaminant-free marijuana and other high demand cannabis-based goods. The Company's strategy involves acquiring cash flowing established companies and organizations with growth potential that require capital to scale. Captor works to capitalize upon the combination of its intellectual property (IP) and wide-ranging network of industry relationships.

Captor Capital's dedication is to provide its customers with easy access to a broad array of products supported by first-rate service. Its stores are stylish, comfortable and designed for customers' enjoyment. The expectation is that the Company's revenue will surpass a run rate of $45 million, via ownership of leading brands and high value dispensary locations.

Last month, Captor Capital announced it qualified for trading on the OTCQX® Best Market (OTCQX). The Company upgraded to OTCQX from the Pink® market. The OTCQX Market is reserved for established, investor-focused U.S. and international companies that meet high financial standards, provide timely news and disclosure to investors.

Additionally, in March, Captor Capital announced that a wholly-owned subsidiary of the Company entered into a Letter of Intent (LOI) to acquire 100 per cent ownership of a Type 7 Volatile Solvent Extraction facility based in California from People's Holdings. People's is one of the largest manufacturers of THC concentrates in California. The facility is 4,000 square feet with trim supplier and distribution agreements in place producing AA-AAA quality THC distillate oil with a 90-95 percent cat3 pass rate.

This week, Captor Capital announced it entered into an LOI to form a Joint Venture Company (JVCo) with Green Buddha Group LLC, a company with significant cannabis assets in Michigan, including retail operations presently generating sales, and cultivation and manufacturing facilities now under development.

With this LOI, Green Buddha will transfer to JVCo Michigan licenses to operate 20 retail medical cannabis retailers, two licenses to operate a cannabis manufacturing, processing, and extraction facility, and eight licenses to operate a 325,000 sq. ft. cannabis cultivation facility (the Michigan Licenses). Captor Capital has agreed to provide JVCo a convertible loan to finance the exploitation of the Michigan Licenses and the build-out and operation of JVCo's retail processing and cultivation facilities.

The loan is convertible into 50.1 per cent of the issued and outstanding shares of JVCo. Upon conversion of the loan, Green Buddha Group would own 49.9 per cent of JVCo.

Captor Capital Corp. (CPTRF), closed Thursday's trading session at $1.26, down 3.08%, on 16,665 volume with 24 trades. The average volume for the last 3 months is 13,418 and the stock's 52-week low/high is $0.55/$2.14.

chart

Exactus, Inc. (EXDI)

NetworkNewsWire, Penny Stock Tweets, Trading View, OTC Presswire, Zacks, Stockhouse, InvestorsHub, Barchart, Morningstar, The Street, Proactive Investors, Marketbeat, Investors Hangout, Stockopedia, Market Screener, YCharts, Wallet Investor, Stockwatch, MarketWatch, and 4-Traders reported on Exactus, Inc. (EXDI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Exactus, Inc. is a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products. In addition, the Company is developing point of care diagnostics. Exactus sells its CBD products direct to consumers by way of its Hemp Healthy® brand. It also sells white label products to third-party resellers. Exactus has its corporate office in Delray Beach, Florida.

Furthermore, Exactus engages in producing industrial hemp from farms in Oregon. Its plan is to extract and manufacture directly through cGMP facilities. Exactus One World is the name of the Exactus farming and production initiative.

With the acquisition of Hemp Healthy, Exactus' plan is to introduce and launch additional CBD products this year. The Company states that Hemp Healthy will continue to serve as an information resource and leader in the CBD market place through setting the industry standards on transparency and quality with every product. Moreover, the Hemp Healthy platform also offers a sales affiliate program for medical professionals and social influencers.

On January 8, 2019, Exactus entered into a Master Product Development and Supply Agreement with Ceed2Med. Ceed2Med utilizes cGMP facilities and with the Agreement, Exactus has been allotted a minimum of 50 and up to 300 kilograms per month, and up to 2,500 kilograms annually, of active phyto-cannabinoid (CBD) rich ingredients for resale. Exactus offers tinctures, edibles, capsules, and topical solution products manufactured for use by Ceed2Med. Ceed2Med is a worldwide sourcing and distribution platform for industrial hemp and industrial hemp-derived products.

Last month, Exactus announced it appointed Mr. Emiliano Aloi as President. Before his appointment to President, Mr. Aloi has served as a member of the Exactus Advisory Board. Prior to joining Exactus, he began working in the hemp industry in 2014 in Uruguay, where he achieved the first nation-wide agricultural permit for flower cultivation in 2016. In 2018, he co-founded Ceed2Med, LLC.

Exactus, Inc. (EXDI), closed Thursday's trading session at $1.54, up 23.20%, on 14,491 volume with 21 trades. The average volume for the last 3 months is 185,394 and the stock's 52-week low/high is $0.048/$4.00.

chart

Planet 13 Holdings, Inc. (PLNHF)

Small Cap Power, Stockhouse, Trading View, Micro Cap Daily, Wallet Investor, Midas letter, Proactive Investors, Insider Financial, Smarter Analyst, Pot Network, MarketWatch, MicroSmallCap, Barchart, New Cannabis Ventures, and Pot Stock News reported previously on Planet 13 Holdings, Inc. (PLNHF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Planet 13 Holdings, Inc. is a foremost vertically-integrated Nevada cannabis company listed on the OTC Markets' OTCQB. The Company has award-winning cultivation, production and dispensary operations in Las Vegas, Nevada. Planet 13's emphasis is on providing a premier dispensary experience and optimizing cultivation efficiencies via its best-in-class technology, as the vanguard of cannabis. Planet 13 Holdings is headquartered in Las Vegas.

On November 1, 2018, Planet 13 opened the largest, most advanced retail dispensary worldwide immediately next to the Las Vegas strip. The Company has greater than six Cannabis Licenses and is fully licensed for cultivation, retail distribution and more in the fast growing Nevada market.

Planet 13 offers first-rate quality recreational cannabis, cannabis extracts, as well as infused products. Its brands include Planet 13 Las Vegas, Medizin, and TRENDI. Medizin provides a quality assortment of award-winning products. Medizin grows medicinal marijuana and all Medizin plant genetics are hand-selected. TRENDI specializes in expertly crafted cannabis products that create the trend. TRENDI employs leading edge technology and an innovative visual approach to deliver a premier product.

Last month, Planet 13 Holdings announced it signed a Purchase Agreement with Mike Tyson's cannabis venture, Tyson Ranch (TR), to be the exclusive launch partner of Tyson Ranch products in Nevada. Additionally, this Agreement includes marketing appearances by 'Iron Mike' at the Planet 13 Cannabis Entertainment Complex (the SuperStore). Tyson Ranch products will be available on Superstore shelves on April 13, 2019. Mike Tyson will attend the launch, offering autographs, pictures, and raffling memorabilia and prizes for Planet 13 customers.

Last week, Planet 13 Holdings announced that it launched its third wholly-owned brand, Leaf & Vine, following the considerable success of its Medizin line of connoisseur focused products and the TRENDI line of compact, easy-to-use disposable vape and concentrate products. Leaf & Vine products became available on Superstore shelves April 3, 2019.

Furthermore, last week, Planet 13 Holdings announced monthly statistics for the Planet 13 Las Vegas Cannabis Entertainment Complex, (the SuperStore) since opening November 1, 2018.

Mr. Larry Scheffler, co-Chief Executive Officer of Planet 13 Holdings, said, "We opened Phase 1 of the 112,000 square foot Planet 13 Cannabis Entertainment Complex, a 16,200 square foot dispensary, on November 1st, 2018 and I am very pleased to announce that in March we had 1,987 paying customers per day at an average ticket of $89.17. Monthly revenue in March was over $5 million based on only 15 percent of the total square footage we have on-site, adjacent to the Las Vegas Strip."

Planet 13 Holdings, Inc. (PLNHF), closed Thursday's trading session at $2.30, down 0.06%, on 683,401 volume with 499 trades. The average volume for the last 3 months is 230,843 and the stock's 52-week low/high is $0.5015/$2.6695.

chart

Helix TCS, Inc. (HLIX)

Green Market Report, Awesome Penny Stocks, Stockhouse, Dividend Investor, MarketWatch, InvestorsHub, Stock Daily Review, The Street, The Daily Marijuana Observer, Insider Financial, Market Screener, Stockopedia, Stockwatch, Uptick News Wire, Marketwired, The Stock Rover, Market Exclusive, Simply Wall St, and Business Insider reported earlier on Helix TCS, Inc. (HLIX), and we also report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Helix TCS, Inc. is a provider of integrated operating environment solutions for the legal cannabis Industry. The Company has acquired Cannabase, which is the oldest and largest wholesale platform in the cannabis industry. Helix TCS' mission is to provide clients with the most powerful and innovative integrated operating environments in the market. This is to help clients better manage and reduce risk while they focus on their core business. BioTrackTHC is a wholly-owned subsidiary of Helix TCS. Helix TCS is headquartered in Greenwood Village, Colorado.

Helix TCS provides a technology platform that enables clients to manage inventory and supply costs through Cannabase. The Company's services include Technology, Compliance, and Security.

Regarding Security, Helix TCS offers Transport, Armed and Unarmed Guarding, Training, Investigation, and Special Services. Security is its flagship service offering. Concerning Compliance, Helix TCS has a broad array of compliance services for companies in the Cannabis Industry. This safeguards clients' ability to operate while increasing their access to services.

In 2017, the Company acquired Security Grade Protective Services, Ltd.  Security Grade operates as a wholly-owned subsidiary of Helix TCS. Security Grade is a Denver, Colorado-based security firm that provides a range of custom, full-service security solutions to cannabis business customers.

Helix TCS, with its strategic capital partner, Rose Capital, announced in June 2018 the closing of its merger with Bio-Tech Medical Software, Inc. (dba BioTrackTHC). The merger closed on June 1, 2018. Bio-Tech Medical Software, via its BioTrackTHC division, develops and licenses product traceability, inventory management, and Point-of-Sale (POS) software systems for the developing medical and recreational cannabis industry.

Furthermore, Helix TCS acquired software development firm Engeni. This acquisition closed on August 3, 2018.  Engeni, located in Buenos Aires, specializes in developing sales, marketing, and client service applications for SMEs in an assortment of languages. Engeni has been a strategic partner of Helix TCS since April of 2017.

Earlier this month, Helix TCS announced that it acquired Amercanex International Exchange. This one of the first and most influential cannabis electronic trading platforms in the legal cannabis industry. This acquisition provides Helix TCS with a sophisticated Electronic Communications Network (ECN) that can integrate blockchain technology to facilitate real-time transactions of wholesale cannabis product between licensed operators in regulated markets.

This acquisition further expands Helix TCS' Critical Infrastructure Services Platform. This platform enables new and already operating cannabis businesses, and also ancillaries and governments, to manage mission critical infrastructure in their supply chain, inventory, and compliance functions.

Moreover, this month, Helix TCS announced that its subsidiary, BioTrackTHC, was presented with an award for Excellence in Innovation in the category of Business Strategy and Innovation by the National Cannabis Industry Association (NCIA). NCIA is the largest and longest running non-profit association in the legal cannabis industry.

The award was presented February 14, 2019 during NCIA's Seed to Sale Show in Boston, Massachusetts. The Company was also recently recognized as the #1 revenue generating point of sale provider by Cannabis Business Executive and the leader in commercial dispensary point of sale market share by Cannabiz Media.

Helix TCS, Inc. (HLIX), closed Thursday's trading session at $2.162, up 1.98%, on 60,364 volume with 125 trades. The average volume for the last 3 months is 74,043 and the stock's 52-week low/high is $0.771/$3.29.

chart

Newgioco Group, Inc. (NWGI)

Simply Wall St, Investor Place, Wallmine, MarketWatch, Investors Hangout, Barchart, Wallet Investor, The Street, OTC Markets, Cantech Letter, Stockhouse, InvestorsHub, TradingView, and last10K reported earlier on Newgioco Group, Inc. (NWGI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Newgioco Group, Inc. is a betting software technology business. The Company provides regulated leisure lottery and gaming products and services by way of licensed subsidiaries based in Europe. Newgioco has fully licensed online and land-based gaming operations in Italy and Austria. Newgioco Group, together with its wholly-owned subsidiaries, is a fully-licensed and integrated gaming software technology enterprise. OTCQB-listed, Newgioco Group is based in Toronto, Ontario.

The Company acquired Multigioco Srl, a licensed gaming operator headquartered in Rome, Italy. Newgioco's plan is to aggressively pursue attractively priced, fragmented, and profitable gaming operators in Italy. Its goal is to become a top-tier gaming operator over a five-year investment time horizon.

Newgioco Group provides its clients a comprehensive set of leisure gaming products and services. These include sports betting, virtual sports, online casino, poker, bingo, lottery, as well as interactive games and slots.

The Company conducts its business chielfy through retail neighborhood betting shops and an internet-based gambling and sports betting software platform under the registered brand Newgioco, via its licensed website www.newgioco.it in Italy. Additionally, Newgioco offers a unique betting platform (www.odissea.at) providing B2B (Business-to-Business) and B2C (Business-to-Consumer) bet processing.

Newgioco presently reaches online user accounts, web cafes, and land-based gaming locations through three core distribution channels. These channels are Sporting Stores (agencies or arcades), Sporting Points (corners), and Virtual Reload Points (shop, web cafes or websites).

Newgioco Group has launched CHATBOT, its initial phase of Artificial Intelligence (AI) technology incorporated into its innovative ELYS betting platform by Odissea. CHATBOT is an inventive AI betting technology using customized pattern recognition and machine-learning algorithms to determine the relevant features of customer interactions and to develop a complete customer betting profile.

Earlier this month, Newgioco Group announced that it completed the acquisition of Virtual Generation Limited (VG), a foremost developer of virtual gaming software, together with Naos Holding Limited, a private holding company, effective January 30, 2019 for roughly $4.5 million in a combination of cash and stock. Newgioco's plan is to use the VG platform for racing, keno, American Roulette and other casino games, within its ELYS platform. Concurrently, the Company plans to introduce the VG product line into the regulated Italian market, using Newgioco's existing Italian ADM platform certification.

Newgioco Group, Inc. (NWGI), closed Thursday's trading session at $0.37, up 15.62%, on 18,500 volume with 5 trades. The average volume for the last 3 months is 26,593 and the stock's 52-week low/high is $0.25/$1.779.

chart

Propanc Biopharma, Inc. (PPCB)

InvestorsHub, MicroCapDaily, OTC Markets, Marketbeat, Wallet Investor, Insider Financial, Stockhouse, Market Screener, 4-Traders, The Street, Stockopedia, Investing News, Real Investment Advice, Morningstar, and Dividend Investor reported previously on Propanc Biopharma, Inc. (PPCB), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Propanc Biopharma, Inc. is a clinical stage Biopharmaceutical Company that focuses on the development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian, and colorectal cancers. The Company has developed a formulation of anti-cancer compounds that exert manifold effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc Biopharma is headquartered in Melbourne, Australia.

Propanc is developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumour recurrence and metastasis. Its lead product is PRP. This is a novel, patented, formulation comprising two proenzymes mixed in a synergetic ratio.

PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, for the treatment of pancreatic cancer. PRP is an enhanced proenzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically.

Propanc Biopharma has received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the use of PRP. The approved indication is one of the most lethal malignancies with a median survival of 6 months and a 5-year survival rate of less than 5 percent.

The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. After extensive laboratory research and a limited amount of human testing, Propanc Biopharma has evidence that PRP reduces cancer cell growth via promotion of cell differentiation; enhances cell adhesion and may suppress metastasis progression; and has no serious side effects and improves patient survival.

Recently, Propanc Biopharma announced that a cooperation agreement was entered into between the University of Jaén and Propanc to begin the POP1 joint drug discovery program to be co-funded by both parties. This agreement coincides with the appointment of research scientist, Mr. Aitor González, to lead the drug discovery and research activities over the next 3 to 4 years. The aim of this program is to identify and develop suitable backup compounds to Propanc's lead product candidate, PRP. As part of the agreement, Macarena Perán, Ph.D. and Julian Kenyon, M.D. were appointed as joint supervisors, representing the University and Propanc Biopharma, respectively.

Propanc Biopharma, Inc. (PPCB), closed Thursday's trading session at $0.0102, up 0.99%, on 3,544,299 volume with 49 trades. The average volume for the last 3 months is 4,262,369 and the stock's 52-week low/high is $0.0039/$0.2888.

chart

Indoor Harvest Corp. (INQD)

Orbit Stocks, Awesome Penny Stocks, CFN Media Group, InvestorsHub, Stockhouse, Cannabis Financial Network News, Massive Stock Profits, Make Penny Stocks Great Again, SmallCapVoice, MarketWatch, Microcap Daily, Fast Money Alerts, Stock Shock and Awe, OTPicks, Penny Stock General, and PennyPickAlerts reported earlier on Indoor Harvest Corp. (INQD), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Indoor Harvest Corp. is a developer of personalized cannabis medicines. In addition, the Company is a provider of advanced cultivation technology, methods, and processes. Indoor Harvest provides the cannabis industry production platforms for Building Integrated Agriculture (BIA) production. Established in 2011, the Company has its corporate headquarters in Houston, Texas. It is now moving its base of operations and focus to the Boston, Massachusetts area to leverage what it believes to be an attractive environment for cannabis companies since Massachusetts has legalized medicinal and recreational cannabis.

Indoor Harvest has transitioned into a producer of cannabis for research and pharmaceutical development. The Company's patent pending aeroponic methods allow for the production of chemically consistent, contaminate free cannabis, economically at scale.

Indoor Harvest is a pending applicant to produce cannabis under the Texas Compassionate Use Program and is seeking additional licenses in the State of Massachusetts. The Company is moving its operational emphasis to Boston, Massachusetts.

Indoor Harvest has entered into a non-binding Memorandum of Understanding (MOU) to explore the creation of a joint venture (JV) partnership with Cannabis Community Care and Research Network (C3RN) and Integrated Genetics & BioPharma Research (IGBR). Indoor Harvest's plan is to work with C3RN and IGBR to develop a plan to acquire or lease properties and pursue research and development (R&D) initiatives. Additionally, the Company expects to have the ability to offer contract research services and product development services to the cannabis community at large.

The proposed JV will work to identify and publish best practices for cultivation of cannabis via rigorous R&D. Moreover, the JV group aims to provide data and develop partner-specific research studies and goals with academic and other research institutions.

Indoor Harvest's Management is working to deploy its integrated aeroponic technology platform, on its own and with partners in the Boston area, to demonstrate and highlight the Company's belief in the technology's ability to considerably decrease operating costs while boosting yield and quality.

Indoor Harvest Corp. (INQD), closed Thursday's trading session at $0.0374, up 1.36%, on 3,500 volume with 4 trades. The average volume for the last 3 months is 167,770 and the stock's 52-week low/high is $0.0305/$0.288.

chart

Avalon GloboCare Corp. (AVCO)

NetworkNewsWire, Real Investment Advice, InvestorsHub, Stockwatch, Penny Stock Hub, OTC Markets, Information Vine, Wolf Street, Wallet Investor, Simply Wall St, Dividend Investor, Trading View, Dynamic Wealth Research, Business Insider, Investors Hangout, Proactive Investors, and Whale Wisdom reported previously on Avalon GloboCare Corp. (AVCO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Avalon GloboCare Corp. provides healthcare services in the United States and China. The Company operates by way of its primary platforms: Avalon Cell and Avalon Rehabilitation. The Company is a premier healthcare management provider and biotechnology developer. Its dedication is to integrate and manage global healthcare resources. Avalon GloboCare is headquartered in Freehold, New Jersey.

The Company has established a new wholly-owned U.S. subsidiary, Avactis Biosciences, Inc. This subsidiary will center on fast-tracking commercial activities related to its proprietary Chimeric Antigen Receptor (CAR)-T technologies.

Furthermore, Avalon GloboCare has formed a strategic partnership with Weill Cornell's cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering headed by Dr. Yen-Michael Hsu. This strategic partnership aims to co-develop bio-production and standardization procedures in procurement, storage, processing, clinical study protocols, and bio-banking for Chimeric Antigen Receptor (CAR)-T therapy, in accordance with the Foundation of Accreditation for Cellular Therapy (FACT) and American Association of Blood Banks (AABB) standards.

Avalon GloboCare, via its subsidiary, "Avalon RT9 Properties, LLC", involves in the acquirement and management of healthcare facilities. Concerning the Company's healthcare facility, it presently includes healthcare property management services, chiefly through acquiring and managing healthcare real estate facilities, stem cell banks, and a CAP-certified laboratory, which will complement its existing platforms.

The "Avalon Rehabilitation" platform is a turnkey, comprehensive set of rehabilitation services. These services include PT, OT, robotic engineering, cybernectics, and clinical nutrition. The "Avalon Cell" platform centers on cell-based therapies and technologies. Its emphasis is in the field of in vitro diagnostics, regenerative medicine, as well as cancer immunotherapy.

Avalon Cell focuses on transformative and high-impact cell-based bio-technology opportunities in the United States and China. It subsequently fast tracks these to clinical development and commercialization around the world.

Avalon GloboCare's majority-owned subsidiary is GenExosome Technologies, Inc. GenExosome acquired 100 percent of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. GenExosome also entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, Chief Executive Officer of GenExosome Beijing, where GenExosome acquired all assets, including all intellectual property (IP), patents and patent applications held by Dr. Zhou regarding the researching, developing, and commercializing exosome technologies.

Moreover, Avalon GloboCare has its Epicon Biotech Co. Ltd. joint venture (JV) with Jiangsu Unicorn Biological Technology Co. Ltd., within the Nanjing BenQ Hospital. This is a prestigious Grade 3A medical center in Jiangsu Province, China. Avalon formed the JV with Jiangsu Unicorn to create a provincial network of translational cellular therapies and bio-banking programs.

Last month, Avalon GloboCare and its subsidiary Genexosome Technologies announced the discovery and development of the world's first saliva-based exosomal microRNA biomarker, miR-185, as a dual diagnostic and therapeutic target for oral cancer. In collaboration with Beijing Stomatological Hospital affiliated with the Capital Medical University in China, Avalon GloboCare and Genexosome Technologies completed a clinical study and revealed miR185 as a novel saliva-based exosomal biomarker with strong correlation and predictive value for malignant transformation from oral leukoplakia to oral cancer.

Last week, Avalon GloboCare announced that its continuing co-development program with Weill Cornell Medicine, led by Yen-Michael Hsu, M.D., Ph.D., Director of cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering, identified novel human angiogenic exosomes/extracellular cellular vesicles (EV) derived from endothelial cells. The angiogenic exosomes contain angiogenic factors developed to promote new blood vessel formation and tissue regeneration upon release from exosomes.  

Avalon GloboCare Corp. (AVCO), closed Thursday's trading session at $4.85, up 6.59%, on 49,927 volume with 753 trades. The average volume for the last 3 months is 765,269 and the stock's 52-week low/high is $1.45/$13.50.

chart

Cardax, Inc. (CDXI)

Zacks, Street Insider, The Street, 4-Traders, Stockopedia, Morningstar, InvestorsHub, Market Exclusive, MarketWatch, GuruFocus, last10k, Barchart, Stockhouse, and Street Insider reported earlier on Cardax, Inc. (CDXI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cardax, Inc. is a development stage Life Sciences Company listed on the OTCQB. It dedicates primarily all its efforts to developing consumer health and pharmaceutical products that it believes will provide many of the anti-inflammatory benefits of steroids or NSAIDS through targeting many of the same inflammatory pathways and mediators, however with exceptional safety profiles. Cardax has its corporate headquarters in Honolulu, Hawaii.

The Company is preparing proprietary nature-identical products and related derivatives via total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated. This includes, but is not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease.

Cardax's initial main focus is its astaxanthin technologies. Astaxanthin is a strong and safe, naturally occurring, anti-inflammatory and anti-oxidant without the adverse side effects characteristic of anti-inflammatory treatments using steroids or NSAIDS (including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding).

The Company's ZanthoSyn® is its first product to help consumers safely address their inflammatory health. Cardax says that ZanthoSyn® is a physician recommended, anti-inflammatory supplement for health and longevity that features astaxanthin with optimal absorption and purity. ZanthoSyn® contains astaxanthin, which is Generally Recognized as Safe (GRAS) according to Food and Drug Administration (FDA) regulations. The safety and efficacy of the Company's product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.

This past October, Cardax announced it launched its Cardiovascular Health Astaxanthin Supplement Evaluation (CHASE) clinical trial targeting cardiovascular inflammatory health. The first subject was dosed on September 19, 2018. This randomized, double-blind, placebo-controlled CHASE clinical trial will evaluate the effect of low-dose and high-dose ZanthoSyn® on cardiovascular health, as measured by C-Reactive Protein (CRP) levels, over 12 weeks in up to 360 subjects with documented cardiovascular risk factors. Additionally, the study will include an optional open label extension through 48 weeks.

In December 2018, Cardax and GNC announced that they are expanding the sales and marketing program for ZanthoSyn®. GNC is the exclusive brick-and-mortar retail channel for ZanthoSyn®. GNC will augment Cardax's sales and marketing efforts with additional initiatives to boost ZanthoSyn® product awareness and education among GNC store associates and customers nationwide.

Cardax, Inc. (CDXI), closed Thursday's trading session at $0.18, up 5.88%, on 3,000 volume with 1 trade. The average volume for the last 3 months is 19,041 and the stock's 52-week low/high is $0.17/$0.34.

chart

Jones Soda Co. (JSDA)

Actual Gains, MarketWatch, Stock Twits, The Street, Wealthpire, Investor Update, SmallCapVoice, PennyStockRumors, PricelessPennyStocks, SmarTrend Newsletters, TopStockAnalysts, Stock Analyzer, SuperNova Elite, Dividend Opportunities, and Stockhouse reported previously on Jones Soda Co. (JSDA), and today we are highlighting Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Jones Soda Co. is a leader in the premium soda category. The Company has a reputation for its unique flavors and branding. Jones Soda markets and distributes premium beverages under the Jones® Soda, Jones Zilch®, and Lemoncocco™ brands. Jones Soda sells across North America in glass bottles, cans and on fountain through traditional beverage outlets, restaurants, and alternative accounts. The Company is based in Seattle, Washington. Jones Beverages International is a subsidiary of Jones Soda.

Jones Soda is made with pure cane sugar. The Company's varied product line includes pure cane sugar soda, zero-calorie soda, and an all-naturally sweetened sparkling beverage with only 30 calories and 8 grams of sugar.

The Jones Soda portfolio includes Jones Pure Cane Soda, Jones Sugar Free, Jones Cane Sugar fountain products, Spiked Jones (a hard cider soda created for the Company's 21+ market) and its sister brand Lemoncocco, which is a non-carbonated beverage inspired by the icon beverage stands in Rome, Italy. The Lemoncocco™ product is flavored with the extracts of Sicilian lemons and a bit of coconut cream. Lemoncocco™ is a natural beverage, lightly sweetened with a little cane sugar. It is 90 calories per 12 ounce serving. Moreover, it is dairy free and gluten free.

7-Eleven, Inc. and Jones Soda have partnered and created 7-Select® brand premium sodas crafted by Jones. This is the first premium carbonated beverage in the 7-Select private brand line-up. Each 7-Select premium soda is made with natural flavors, lightly sweetened with cane sugar, and ranges from only 180 to 195 calories per 20-ounce bottle. This brand includes 75 mg. of caffeine in each serving.

In January, Jones Soda announced it launched Jones Ginger Beer and two new sugar free soda flavors. This is while transitioning to natural colors and natural flavors in most of its glass bottle portfolio. Unique to Jones Ginger Beer is its signature packaging. This packaging includes a resealable cap that makes this offering ideal for foodservice accounts. In addition, Jones Soda is adding sugar free versions of Strawberry Lime and Cream Soda, two of its top-selling flavors, to its United States portfolio.

Jones Soda Co. (JSDA), closed Thursday's trading session at $0.6412, up 7.76%, on 158,281 volume with 92 trades. The average volume for the last 3 months is 196,403 and the stock's 52-week low/high is $0.219/$0.819.

chart

The QualityStocks Company Corner

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF)

The QualityStocks Daily Newsletter would like to spotlight Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF).

Chemistree Technology Inc. (CSE: CHM and CHM.wt) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to announce the appointment of Mr. Sheldon Aberman to the newly-created position of Chief Cannabis Officer.  This addition will further strengthen its team and advance the Company's international expansion strategy, cultivation practices and results in terms of yield, quality, consistency and cost-effectiveness as it continues to execute across these areas and solidify its position as a world leader within the industry.

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF), an investment company focused on the U.S. and international cannabis sectors, provides turnkey solutions for the regulated cannabis industry. The company leverages managements' expertise and decades of experience in the cannabis industry to acquire and develop vertically integrated cannabis assets. Chemistree recently closed on a purchase of prospective cannabis cultivation property in California, made a first investment in the Canadian cannabis industry, owns assets in the State of Washington used to operate an established retail cannabis brand, and has an active pipeline of assets in place to grow its portfolio.

Chemistree offers industry leading expertise across all areas the cannabis business and in its growth as a public or private company.

  • Investment and funding for rapid growth
  • Vertical integration solutions
  • Construction, design and/or optimization of indoor or outdoor cultivation facilities
  • Reputation management & influencer outreach
  • Branding and Packaging
  • Social Media and Media outreach

With the marketing of cannabis companies and their products in its infancy, the company believes the industry offers tremendous opportunity for growth in the U.S. and abroad. Chemistree initially targeted the Pacific Northwest for investment and, following its recent California property purchase, expects to expand vertically across the United States in areas where it has a competitive business advantage.

Through its wholly owned CHM Desert LLC subsidiary, Chemistree owns 9.55 acres of undeveloped land in Desert Hot Springs, California. The property is zoned as Light Industrial Lands Designated for Marijuana Cultivation, and local zoning ordinances allow as a conditional use the location of up to three onsite cannabis cultivation buildings of 68,000 square feet each, along with support space that would support production of 55,000 pounds/year.

Through its wholly owned Chemistree Washington Ltd. subsidiary, Chemistree acquired physical assets used in the cultivation, production and distribution of cannabis. The Washington assets are currently under lease to Sugarleaf Farm LLC, which operates the Sugarleaf brand of retail cannabis products in the State of Washington. Sugarleaf Farm is a Tier 3 cannabis producer and processor whose products are sold in about 125 retail outlets. Chemistree has indicated the relationship with Sugarleaf may provide the company with additional opportunities to become involved in the marketing of Sugarleaf products.

Chemistree funded these acquisitions and investments with the proceeds of two non-brokered private placement financings completed earlier this year under the regulations of the Canadian Securities Exchange, totaling CAD$4.5 million. In conjunction with the private placements, the company was granted approval by the CSE for a change of business to become an Investment Issuer. This funding is expected to provide the company "maximum flexibility to take advantage of the numerous opportunities available in the cannabis industry in Canada and the U.S."

Chemistree also has a strategic investment in Pasha Brands Ltd., a British Columbia based cannabis company with multiple internationally recognized brands. Pasha has a proven history in cannabis retailing and its proposed Licensed Processing (LP) facility on Vancouver Island is in the final stage of the application for government approval. The LP facility is expected to assist in licensing selected craft growers of cannabis and expanding the distribution of locally grown product. The investment represents less than 10% of Chemistree's working capital.

Company Chairman Justin Chorbajian is co-owner of the largest chain of privately owned hydroponic retail shops in Canada. He also cofounded a group of companies that manufacture and distribute hydroponic equipment. He is a frequent contributor to Growing Exposed, the leading video series dedicated to cannabis cultivation. Company President Karl Kottmeier is a former investment advisor with 20 years of experience listing, financing and administering companies on the Toronto Stock Exchange and TSX Venture Exchange. He has raised more than $150 million in equity capital for ventures. Chemistree CFO Doug Ford has been general manager of Dockside Capital Group Inc., a private merchant banking and venture capital firm serving emerging growth companies. Sheldon Aberman, the most recent member of the Board, has managed, designed and created industry leading grow room designs around the world. Additionally, he has built several leading brands such as Frost Box and Black Label and is an expert in the accessory market (vape pens, silicon mats and extraction tools etc.).

Data firm Statista has forecast the U.S. legal cannabis market will be worth more than $24 billion by 2025. New Frontier Data, which focuses exclusively on the cannabis industry, projects the value of the Canadian domestic cannabis market that same year at CAD$9.2 billion.

Chemistree Technology Inc. (CHMJF), closed the day's trading session at $0.4336, off by 2.63%, on 71,536 volume with 39 trades. The average volume for the last 3 months is 32,404 and the stock's 52-week low/high is $0.268/$0.605.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (OTCQB: SGMD), a major supplier to the growing hydroponic cultivation sector, today announces the signing of a supply contract with Hempistry, Inc. where the Kentucky-based hemp cultivator is acquiring supplies for its hemp micropropagation operation.  Sugarmade expects this supply relationship to be ongoing as Hempistry expands its operations, both domestically and internationally.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.04825, up 4.66%, on 1,344,525 volume with 129 trades. The average volume for the last 3 months is 1,292,700 and the stock's 52-week low/high is $0.0425/$0.209.

Recent News

chart

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

Royalty company for the U.S. licensed medical cannabis industry FinCanna Capital (CSE: CALI) (OTCQB: FNNZF) today announced its appointment of Harborside's wholesale and distribution manager Dani Walton to its board of advisors. To view the full press release, visit: http://nnw.fm/qL6oI.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.1066, up 7.44%, on 5,000 volume with 1 trade. The average volume for the last 3 months is 33,125 and the stock's 52-week low/high is $0.0577/$0.50.

Recent News

chart

Trxade Group Inc. (TRXD)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (TRXD).

Financial results show that 2018 was a successful year of growth for Trxade Group Inc. (OTCQB: TRXD), an integrated drug purchasing and delivery solutions company with a platform that enhances supply chain efficiencies among health care buyers and sellers of pharmaceuticals, accessories and services. The company recently presented its report for the final quarter of 2018, highlighting a number of key accomplishments (http://nnw.fm/Dq3JZ).

Trxade Group Inc. (TRXD) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade's overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company's pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, "E-Bay/Kayak-like" technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the "consumer side" of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called "Delivmeds" (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade's Managed Services Organization ("TrxadeMSO") enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient's information, thereby ensuring appropriate medication coverage based on the patient's location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade's fair online market platform targets the nation's retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE's programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks ("PAC") to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry.
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE's advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process.

Management Team

Trxade's management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary

Suren Ajjarapu has served as Trxade's chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer

Prashant Patel has served as Trxade's full-time president and COO, and as a director since the company's acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (TRXD), closed the day's trading session at $0.54, even for the day. The average volume for the last 3 months is 2,027 and the stock's 52-week low/high is $0.23/$1.00.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) was highlighted today in a publication from Financialnewsmedia.com, examining how 2019 will be a year of maturation and expansion for the cannabis industry.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $3.8275, off by 0.33%, on 65,812 volume with 175 trades. The average volume for the last 3 months is 83,967 and the stock's 52-week low/high is $2.81/$6.008.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood, Inc. (OTCQB: NGTF), the innovative company solving America's $50 billion-dollar nighttime snacking problem, announced today that CEO Sean Folkson has been invited to speak at the 13th Annual Global Dairy Congress in Lisbon, Portugal the week of June 24.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed the day's trading session at $0.70, even for the day, on 181,823 volume with 71 trades. The average volume for the last 3 months is 553,847 and the stock's 52-week low/high is $0.16/$0.92.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full publication, titled "Potential Blockbuster Gene Therapy Programs to Watch in 2019," visit: http://nnw.fm/YC9iq.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed the day's trading session at $1.80, even for the day, 7,938 volume with 56 trades. The average volume for the last 3 months is 49,400 and the stock's 52-week low/high is $0.95/$19.45.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was highlighted today in a publication from Financialnewsmedia.com, examining how, in recent industry reports, China led all countries with nearly $1.2 billion USD in hemp sales in 2018, followed by the United States ($1.0 billion), Europe ($980 million) and South and Central America ($220 million).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $3.12, off by 5.17%, on 867,520 volume with 1,298 trades. The average volume for the last 3 months is 1,424,727 and the stock's 52-week low/high is $1.607/$7.894.

Recent News

chart

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company's (TSX.V: FIRE) (OTCQX: SPRWF) (FRA: 53S1) 7ACRES subsidiary is expanding its cultivation facility space. The expansion is set to increase its production capacity by 50%, reaching approximately 26,250 kg. To view the full article, visit: http://nnw.fm/x4WhD. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how, in recent industry reports, China led all countries with nearly $1.2 billion USD in hemp sales in 2018, followed by the United States ($1.0 billion), Europe ($980 million) and South and Central America ($220 million).

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.4696, off by 4.32%, on 568,221 volume with 569 trades. The average volume for the last 3 months is 678,212 and the stock's 52-week low/high is $0.85/$2.04.

Recent News

chart

Kontrol Energy Corp. (CSE: KNR) (OTC: KNRLF) (FSE: 1K8)

The QualityStocks Daily Newsletter would like to spotlight Kontrol Energy Corp. (CSE: KNR).

Efforts to "save the planet" have for decades turned worries about changes in our natural environment into a variety of climate-friendly endeavors, once leading comedian George Carlin to complain, "Save the planet?! We don't even know how to take care of ourselves yet!" Smart energy efficiency platform developer Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is helping businesses take care of themselves and care for their neighbors while making the earth's climate a little friendlier for humanity in the process.

Kontrol Energy Corp. (CSE: KNR) (OTC: KNRLF) (FSE: 1K8) specializes in the integration of smart energy technologies and solutions for North American commercial and industrial property owners and operators to help them benefit from energy cost savings and minimize greenhouse gas emissions. Kontrol is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology and is ranked by Canadian Business and Maclean’s as the 7th fastest growing startup in 2018.

Kontrol’s leadership position is reshaping the way customers use, manage and strategically allocate energy resources to realize immediate energy savings by gaining more control over energy consumption and demand in real-time.

As the fastest growing global “fuel source,” energy efficiency is big business with industry analysts noting this multi-trillion-dollar market offers significant opportunities over the next five years. Established market segments include: energy retrofits ($71.4 billion); distributed generation ($179.9 billion); energy analytics ($33.5 billion); and greenhouse gas/carbon measurement, reduction ($1.2 trillion). Each $1 invested in energy efficiency displaces up to $3 of utility-scale transmission and distribution investment, according to the International Energy Agency.

Formed in 2015 by a group of energy veterans who recognized that the energy efficiency industry is one of the fastest growing fuel sources for the global economy, Kontrol is committed to enhancing and improving its customers sustainability objectives. In less than two years, Kontrol has grown its revenue run rate to $16 million from $1.8 million, delivering on stated goals and objectives as it seeks to continue this pattern through accretive acquisitions and the expansion of the company’s smart energy technologies.

Up to 50 percent of Kontrol’s overall revenues are recurring annually, and the company’s 2019 outlook includes strategic initiatives that will expand the company’s smart energy technologies to U.S. markets, bring additional accretive and strategic acquisitions, and accelerate recurring SaaS revenues.

Kontrol’s strategy of disciplined mergers and acquisitions includes the following highlights:

  • Acquisition of Log-One Ltd.’s award-winning energy conservation technology, Energy Management System (“EMS”), an intelligent, occupancy-based heating and air-conditioning control system for commercial and multi-residential real estate. Rebranded as Kontrol EMS Technology, the company has added IoT and mobile application capabilities, creating a recurring revenue platform through a Software-as-a-Service (SaaS) platform.
  • Acquisition of ORTECH Consulting Inc., an engineering consulting firm specializing in Greenhouse Gas (GHG) reporting, emission testing, air quality testing and renewable energy/power consulting.
  • Acquisition of Efficiency Engineering Inc. (“EE Inc.”), which provides engineering services to industrial, municipal and commercial building owners across Canada. EE Inc. provides detailed energy efficiency analysis, energy audits, management of facility system solutions, electrical and mechanical design and energy conservation studies.
  • Acquisition of MCW Dimax Ltd. (“MCX”), a firm specializing in solutions for the application of energy software to analyze the management of complex heating, ventilation and cooling systems for large residential, commercial, and mission critical real estate owners.
  • Acquisition of CEM Specialties Inc. (“CEMSI”), a market leader in turn-key emission monitoring, equipment and solutions.

The company has also established entry into the North American cannabis market as a supplier of integrated energy efficiency solutions and technologies. Within this market, Kontrol is focused on assisting cannabis growers to reduce the cost of energy and support mission critical infrastructures. To date, Kontrol has secured two contracts to provide energy efficiency services with Licensed Producers in the Canadian cannabis sector.

The Kontrol Energy group of companies is currently saving its customers more than 40 million kilowatt hours of electricity per annum and providing a corresponding reduction in GHG emissions.

Kontrol’s management team includes CEO Paul Ghezzi, a leader in clean tech, renewable energy development, solar project financing and distributed generation. Ghezzi has global experience in power generation projects under Feed-in Tariff programs and Power Purchase Agreement programs for both commercial and utility-scale projects. COO Kristian Lavereau has more than 25 years of experience in the IT solutions (analytics and mobile computing), energy optimization and efficiency (intelligent control systems, solar PV, lighting). Claudio Del Vasto, CPA, CA | CFO, is a senior finance executive with an extensive background in corporate finance, strategy and business development.

Kontrol Energy Corp. (CSE: KNR), closed the day's trading session at $0.89, off by 1.11%, on 7,200 volume with 9 trades. The average volume for the last 3 months is 37,097 and the stock's 52-week low/high is $0.46/$0.99.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) on Tuesday announced its entry into a non-binding letter of intent ("LOI"), dated April 3, 2019, to acquire City Cannabis Corp. in exchange for common shares of Wildflower. To view the full press release, visit: http://nnw.fm/W6WPj. Also today, the company was featured today in the 420 with CNW by CannabisNewsWire. Additionally, CannabisNewsWire released a report featuring the company which examines the recent news that the CBD market is experiencing explosive growth as a result of growing mainstream acceptance and strong leadership.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.65, off by 0.50%, on 249,823 volume with 66 trades. The average volume for the last 3 months is 16,503 and the stock's 52-week low/high is $0.009/$1.139.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

Ontario-based VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF), a leading provider of first-class cannabis products and services to the medical and adult-use markets, announced on Wednesday that it intends to post the company's financial and operating results for the fiscal fourth quarter and full year 2018 before the markets open on April 30, 2019. To view the full press release, visit: http://nnw.fm/n0kHk.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $0.6561, off by 3.90%, on 391,079 volume with 221 trades. The average volume for the last 3 months is 317,783 and the stock's 52-week low/high is $0.413/$1.53.

Recent News

chart

City View Green Holdings Inc. (CSE: CVGR)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR).

Vertically integrated cannabis company City View Green Holdings (CSE: CVGR) is following its plan to enter the cannabis-edible and beverage markets. The company just entered into a partnership with a leading Jamaican Blue Mountain coffee company. To view the full article, visit: http://nnw.fm/USq0n.

City View Green Holdings Inc.'s (CSE: CVGR) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Management

Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR), closed the day's trading session at $0.13, off by 7.14%, on 210,464 volume with 45 trades. The average volume for the last 3 months is 510,203 and the stock's 52-week low/high is $0.10/$0.465.

Recent News

chart

Global Consortium, Inc. (OTC: GCGX)

The QualityStocks Daily Newsletter would like to spotlight Global Consortium, Inc. (OTC: GCGX).

From its headquarters in Florida, Global Consortium Inc. (OTC: GCGX), a diversified cannabis holding company expanding its reach nationwide with several subsidiaries, is evaluating an opportunity to take one of its divisions public in Canada. Cannabis businesses listed in Canada have historically thrived after going public on the Canadian Stock Exchange ("CSE"), which also allows firms to dual list in the United States, as the company noted in a news release (http://nnw.fm/dLzQ4).

Global Consortium, Inc. (OTC: GCGX) is a diversified cannabis holding company that recently acquired several companies in the cannabis space. Headquartered in Florida, Global Consortium is expanding its reach nationwide with several subsidiaries, partnerships and licensing agreements. Golden Consortium reported over $600,000 in sales in the quarter ended September 30, 2018, and over $2 million in CBD product sales for 2018.

Among Global Consortium’s assets are the following:

  • Infused Edibles has been selling a wide selection of specialty, CBD-infused edible products including gummies, baked goods, fruit and nut mixtures, savory and spicy dried fruits and jerky, and cannabidiol oils for over 13 years. Infused Edibles has received 17 first place awards for its dedicated line of U.S. grown, CBD isolate-infused food products. Infused Edibles operates out of a 6,000 square foot building, servicing 400 stores with dedicated sales reps and eight distributors in 15 states.
  • Infused Oils is a northern California company that produces a premium, 100 percent solvent and pesticide-free cannabis distillate that delivers potency, purity and flavor to medical cannabis patients. Infused Oils uses state-of-the-art CO2 supercritical extraction methods to preserve the delicate cannabinoid and full spectrum terpene profiles of its medical grade oil. Produced from uncommon, boutique cannabis strains that are micro-grown and hand trimmed, Infused Oils creates natural, medicinal cannabis extracts that are strain specific THC and CBD oils of premium quality.
  • America’s first Cannabis Mall, under construction in the Sacramento, California, area, is designed to house cannabis manufacturing, distribution, delivery, retail, testing and cultivation – all under one 64,000 square foot building that showcases various cannabis operations from seed to shelf. The Cannabis Mall will house the largest manufacturing facility of THC and CBD distillates and edibles believed to be operational in the United States. The testing lab at the Cannabis Mall will service outside cannabis vendors as well as all products manufactured there. The distribution space will be leased to a 3rd party with a 50 percent revenue share for Global, while all of Global’s products will be distributed free.

Global Consortium recently entered into a Letter of Intent with MJ Munchies, Inc., a subsidiary of Nightfood Holdings, Inc. (OTC: NGTF), for an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked(TM) mark owned by MJ Munchies. The LOI includes provisions for monthly royalty payments, sales and growth thresholds, and a distribution of proceeds if, and when, the Half-Baked brand is ever sold to a third party.

Global Consortium has also received a weekly order, worth a minimum of $50,000 per week, from the only licensed delivery company servicing the Lake Tahoe, Nevada, area. Over 30 million people live in and visit the Lake Tahoe area, which has no recreational dispensaries. As part of the deal, all of Global’s product lines – Infused Edibles, Indulge Oils and any other products produced – will be offered by the delivery company.

Management

Director, CEO and President Matthew Dwyer has been working in the securities industry since 1986 when he began his career working for Donaldson, Lufkin, and Jenrette. Dwyer went on to hold several securities licenses until 1991 when he ventured off on his own. He has worked in all sectors of the industry from owning an Investors Relations company with one of the first call rooms to working on reverse mergers and debt financing. Dwyer has a well-versed working knowledge of the securities industry, working with both OTC and SEC reporting companies.

Director and incoming President Manuel Losada has over 30 years of healthcare industry experience dedicated to building and achieving profitability and growth. His extensive background includes medical/surgical and device manufacturers, distribution and supply chain, group purchasing organizations, pharmaceuticals and medical product delivery systems. Losada holds a proven track record of successful mergers and acquisitions, business development, and long-range planning for Fortune 500 and multinational companies. He is an energetic professional with exceptional analytical, organizational and people skills, strong personal ethics and integrity. Dwyer is a highly organized team-builder with strong leadership experience and excellent communication skills.

Andrew Moll, Independent Director, has worked as a sales rep for approximately 25 years calling on all types of stores including specialty, resorts, sporting goods, casinos, major department stores and mass merchants. Moll worked in private label production overseas and domestic for NASCAR, Wal-Mart, Coca Cola, Six Flags, Disney, Universal Studios, Sea World, and Hard Rock. In addition, he spent 10 years working with U.S. retailers and apparel brands to secure overseas production with factories in Central and South America as well as China, India, and Pakistan. Moll spent the last 8 years as vice president of sales for a resort athleisure company.

Tom Roland, Chief Operating Officer, is the founder of Indulge Oils. Roland has built a strong reputation in the business over the past 5 years for producing a superior product and delivering on time. He will operate the Cannabis Mall and all manufacturing for both the edibles and distillates departments. Roland is a proven entrepreneur experienced in building profitable companies and has a passion for entrepreneurship, developing innovative approaches to industry challenges, and building vibrant company cultures. He accelerates development and deployment of solutions while maintaining profitable growth. Roland also serves as an advisor to several start-up ventures and continues to empower teams though his provocative leadership.

Marc Adesso, Securities Counsel, of Waller Lansden Dortch & Davis, LLP, is recognized for his work on securities regulation and corporate governance. He has established a national practice counseling issuers, conducting mini-IPOs under Regulation A+ of the JOBS Act, which currently allows companies to raise up to $50 million per year from the general public. Adesso is a key member of the firm’s blockchain and cryptocurrency practice and is lauded as one of the world’s top attorneys in the area of registered offerings of cryptocurrencies such as ICOs. In recognition of his national reputation in the space, as well as being Tennessee’s only veteran cannabis attorney, Adesso chairs the firm’s legalized cannabis practice which counsels clients on the rapidly changing landscape facing the cannabis industry.

Global Consortium, Inc. (OTC: GCGX), closed the day's trading session at $0.0269, off by 1.47%, on 2,457,116 volume with 101 trades. The average volume for the last 3 months is 3,168,551 and the stock's 52-week low/high is $0.016/$0.1083.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.